February 28, 2010 - Patients expressed a statistically significant preference for the taste of iohexol over diatrozoate, a feature that is especially beneficial for very ill patients whom have trouble tolerating the taste of contrast agents, concluded a recent study.
Researchers from Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Missouri and the Milton S. Hershey Penn State Medical Center conducted a study comparing the tolerability of iodine-based oral contrast agents, Omnipaque (iohexol) and Gastroview (meglumine sodium diatrizoate). The purpose of the study was to compare the efficacy and patient acceptance of iohexol verus meglumine sodium diatrozoate for abdominal and pelvic CT scans.
Researchers presented on February 21 at the Abdominal Radiology Course Meeting held by the Society of Gastrointestinal Radiology and The Society of Uroradiology in Orlando.
The study also concluded that:
- There was no statistically significant difference between the two agents in the incidence of adverse reactions.
- The extent and density of GI tract opacification also were similar between the two groups.
- The cost of the two agents is comparable given the current low cost of low osmolar contrast agents.
For more information: www.mir.wustl.edu